New York is currently home to 4447 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Comprehensive Assessment of Cancer Theranostic Response
Recruiting
The intent of this study is to evaluate actionable outputs from TRAQinform Theranostics in a prospective, multi-center, non-interventional clinical study. The primary objective is to investigate intent-to-change treatment decisions after the addition of TRAQinform Theranostics. The exploratory objective is to investigate if treatment efficacy and treatment-related toxicity could be detected by TRAQinform Theranostics following PSMA PET/CT at week 12.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: Weill Medical College of Cornell, New York, New York
Conditions: Prostate Cancer
A Study of Sotorasib in People With Brain Tumors
Recruiting
The researchers are doing this study to find out how effective sotorasib is at getting into KRAS G12C+ brain tumors. The researchers will also find out whether sotorasib is a safe and effective treatment for people undergoing surgical resection of KRAS G12C+ metastatic brain tumors, and do tests that show how the body absorbs, distributes, and gets rid of sotorasib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack, New York
Conditions: Brain Tumor
Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System
Recruiting
The goal of this study is to obtain safety data, establish dose parameters, and effectiveness of treatment for the SpectraCure P18 System with IDOSE®, together with verteporfin for injection (VFI) as photosensitizer, for the treatment of primary localized prostate cancer. The study will be divided into two parts, with Phase I, dose-escalation, to study safety and establish an effective light dose, followed by Phase II, cohort expansion, to evaluate clinical efficacy and confirm safety/tolerabil... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Prostate Cancer
Study to Evaluate the Safety and Effectiveness of the enVista® Beyond (EY) EDF Intraocular Lens in Subjects Undergoing Cataract Extraction
Recruiting
This research study is evaluating the safety and efficacy (performance) of the Bausch + Lomb enVista Beyond Hydrophobic Acrylic Extended Depth of Focus Intraocular Lens (IOL) in subjects who receive this IOL in both eyes.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
02/04/2025
Locations: Site 113, Garden City, New York
Conditions: Cataract
The Computational and Neural Mechanisms Linking Decision-making and Memory in Humans
Recruiting
Learning to make good decisions in the present, and accurately recalling events and information from the past, are critical aspects of human cognition that are often impaired in many psychiatric disorders. This project aims to identify the how the choices individuals make influence what, and how, people remember by combining disparate techniques in computational modeling and direct brain recordings in human subjects. The researcher developed a dual-task paradigm, probing how decisions in one tas... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/04/2025
Locations: Mount Sinai West, New York, New York
Conditions: Memory, Short-Term
Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation ( VISTA-US)
Recruiting
The purpose of this clinical study is to evaluate the safety and clinical efficacy of the VDyne System in the treatment of symptomatic severe tricuspid regurgitation (TR).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Tricuspid Regurgitation, Tricuspid Valve Disease, Tricuspid Valvular Disorders
Different Doses of Naronapride Vs. Placebo in Gastroparesis
Recruiting
This is a double-blind, randomized, multicenter, placebo-controlled, comparative phase II dose-finding trial. The trial will be conducted with four treatment groups in the form of a parallel group comparison and will serve to compare oral treatment with daily doses of 10, 20, or 40 mg Naronapride vs. placebo for the treatment of patients with Gastroparesis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/04/2025
Locations: Dr Falk Investigational Site, New York City, New York
Conditions: Gastroparesis
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
Recruiting
Breast-conserving surgery followed by re-irradiation with partial breast irradiation (rPBI) has recently been found to be a safe alternative to mastectomy for women who have undergone prior whole breast radiation. By reducing the volume of tissue receiving radiation, rPBI has been associated with less toxicity and improved cosmetic outcomes. For many women with early-stage breast cancer, shorter 1-week (5-fraction) courses of breast radiation (ultra-fractionation) have been found to be equivalen... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
02/04/2025
Locations: NYU Langone Health, New York, New York
Conditions: Breast Cancer, Breast Cancer Recurrent
Safety of the Herpes Zoster Subunit Vaccine in Lupus
Recruiting
This randomized, double-blind, placebo-controlled, non-inferiority crossover study will evaluate the Herpes Zoster Sunbit (HZ/su) vaccine in SLE patients in order to evaluate safety and immunogenicity in patients with variable baseline clinical activities, ages and immunosuppressant exposures. The investigators hypothesize that HZ/su administration will be non-inferior to placebo with respect to the risk of moderate or severe SLE flare(s) occurring within 24 weeks of receiving the first dose of... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
02/04/2025
Locations: NYU Langone Health, New York, New York
Conditions: Systemic Lupus Erythematosus
Transcranial Ultrasound Via Sonolucent Cranioplasty After Minimally Invasive Intracerebral Hemorrhage Evacuation
Recruiting
Postoperative rebleeding is a major limitation of surgical evacuation for intracerebral hemorrhage (ICH). While computed tomography (CT) is the standard of care for postoperative hematoma cavity monitoring, CT requires significant physical and financial costs. Studies have demonstrated varying degrees of efficacy when using transcranial ultrasound to measure ICH volume. Recently, synthetic implants for cranioplasty have been shown to be safe and sonolucent. This study aims to evaluate the abilit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: Mount Sinai Health System, New York, New York
Conditions: Transcranial Ultrasound With Sonolucent Cranioplasty, TUSC
Surgical Pembro +/- Olaparib W TMZ for RGBM
Recruiting
This research study is studying a combination therapy as a possible treatment for recurrent glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment. The names of the study interventions involved in this study are/is: * Pembrolizumab * Olaparib * Temozolomide (Temodar)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: Memorial Sloan Kettering Cancer Center, New York City, New York
Conditions: Glioblastoma, Recurrent Glioblastoma
A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80
Recruiting
In this study, researchers will learn more about BIIB122 in participants with early-stage Parkinson's disease (PD). The study will include adults aged 30 to 80 who were diagnosed with PD within 2 years of starting the study. The main objective of the study is to learn about the effect BIIB122 has on slowing down the worsening of PD symptoms. The main question researchers want to answer is: - How long does it take for PD symptoms to worsen during BIIB122 treatment? Researchers will answer this... Read More
Gender:
ALL
Ages:
Between 30 years and 80 years
Trial Updated:
02/04/2025
Locations: Mount Sinai Beth Israel, New York, New York
Conditions: Parkinson Disease